July 5, 2018 Utilizing the expertise of the Baric Lab at the UNC Gillings School, Gilead Sciences is making breakthroughs in developing drugs to fight some of the world’s deadliest viruses. The Gilead broad-spectrum treatment that was tested and proven in the Baric Lab, now known as Remdesivir, was deployed for use in the Ebola outbreak in the Democratic Republic of the Congo.
June 7, 2018 Results from a recent study suggest that human and bat caliciviruses may have evolutionarily descended from a common ancestor, indicating a potential for the bat viruses to cross species barriers and infect humans.
June 28, 2017 Scientists at the Gillings School have confirmed that an experimental antiviral treatment prevents the development of SARS coronavirus disease in mice. The drug, GS-5734, also inhibits MERS-CoV and multiple other coronaviruses (CoV), suggesting that the treatment may inhibit all CoV.
